Prica, A.; Hay, A.E.; Crump, M.; Mittmann, N.; Shepherd, L.E.; Meyer, R.M.; Imrie, K.I.; Risebrough, N.; Djurfeldt, M.; Chen, B.E.;
et al. Evaluating the Indirect Costs of Care Associated with Salvage Chemotherapy for Relapsed and Refractory Aggressive-Histology Lymphoma: A Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial. Curr. Oncol. 2021, 28, 1256-1261.
https://doi.org/10.3390/curroncol28020119
AMA Style
Prica A, Hay AE, Crump M, Mittmann N, Shepherd LE, Meyer RM, Imrie KI, Risebrough N, Djurfeldt M, Chen BE,
et al. Evaluating the Indirect Costs of Care Associated with Salvage Chemotherapy for Relapsed and Refractory Aggressive-Histology Lymphoma: A Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial. Current Oncology. 2021; 28(2):1256-1261.
https://doi.org/10.3390/curroncol28020119
Chicago/Turabian Style
Prica, Anca, Annette E. Hay, Michael Crump, Nicole Mittmann, Lois E. Shepherd, Ralph M. Meyer, Kevin I. Imrie, Nancy Risebrough, Marina Djurfeldt, Bingshu E. Chen,
and et al. 2021. "Evaluating the Indirect Costs of Care Associated with Salvage Chemotherapy for Relapsed and Refractory Aggressive-Histology Lymphoma: A Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial" Current Oncology 28, no. 2: 1256-1261.
https://doi.org/10.3390/curroncol28020119
APA Style
Prica, A., Hay, A. E., Crump, M., Mittmann, N., Shepherd, L. E., Meyer, R. M., Imrie, K. I., Risebrough, N., Djurfeldt, M., Chen, B. E., & Cheung, M. C.
(2021). Evaluating the Indirect Costs of Care Associated with Salvage Chemotherapy for Relapsed and Refractory Aggressive-Histology Lymphoma: A Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial. Current Oncology, 28(2), 1256-1261.
https://doi.org/10.3390/curroncol28020119
